Clinical TrialMay 1, 2026, 07:03 AM
MPLT completes enrollment for 2 Phase 2 trials; results by mid-August 2026
AI Summary
MapLight Therapeutics, Inc. announced the completion of enrollment for its Phase 2 ZEPHYR trial evaluating ML-007C-MA for schizophrenia, involving 307 participants. The company also completed the final patient visit for its Phase 2 IRIS trial evaluating ML-004 for autism spectrum disorder, which randomized 161 participants. Topline results from both randomized, double-blind, placebo-controlled trials are anticipated by mid-August 2026, marking a significant milestone for the clinical-stage biopharmaceutical company.
Key Highlights
- Enrollment completed for ML-007C-MA's ZEPHYR Phase 2 trial in schizophrenia.
- Last patient visit completed for ML-004's IRIS Phase 2 trial in autism spectrum disorder.
- Topline results from both Phase 2 trials are expected by mid-August 2026.
- ZEPHYR trial randomized 307 participants for schizophrenia treatment.
- IRIS trial randomized 161 participants for autism spectrum disorder treatment.
- ZEPHYR primary endpoint: change in PANSS total score from baseline to Week 5.
- IRIS primary endpoint: change in ABI-Social Communication Domain Score from baseline to Week 12.
Price Impact
More from MPLT